StockpollyBeta
Get App
SLNO · NASDAQ · Biotechnology

Soleno Therapeutics (SLNO)

Commercializes VYKAT XR for hyperphagia in Prader-Willi syndrome.

$53.01
0.00 (0.00%)
Delisted · May 15, 2026

Something off on this page? Send us feedback.

13F · 13D/G · Form 4

Insiders0.29%151.2K shares
2 holders · as of Jan 23, 2026
Strategic holders59.78%31.16M shares
5 holders · as of May 15, 2026
Other39.93%20.81M shares
remainder

52.12M company shares as of Sep 23, 2026 · holders as of their latest filing

13F · 13D/G · Form 4

HolderStakeSharesDate
Vivo Ventures V, LLC1Strategic10 percent owner
31.35%15.51Mfiled Dec 3, 2019
Wellington Management Group LLPStrategic
8.49%4.43Mfiled May 15, 2026
Janus Henderson Group PLCStrategic
7.99%4.16Mfiled Oct 3, 2024
Avoro Capital Advisors LLCStrategic
6.80%3.54Mfiled Apr 24, 2026
State Street CorporationStrategic
5.14%2.68Mfiled May 12, 2026
James H. MackanessInsiderofficer: CHIEF FINANCIAL OFFICER
0.25%131,763filed Jan 23, 2026
William G. HarrisInsiderdirector
0.04%19,392filed Jun 9, 2025
683 Capital Management, LLCInstitution
—2.30% of class, as filed—filed Feb 13, 2020
Adage Capital Partners GP, L.L.C.Strategic
—8.69% of class, as filed—filed Oct 12, 2023
Bhatnagar AnishInsiderdirector, officer: CHIEF EXECUTIVE OFFICER
0.00%0filed May 18, 2026
Dawn Carter BirInsiderdirector
0.00%0filed May 18, 2026
Jennifer FulkInsiderofficer: CHIEF FINANCIAL OFFICER
0.00%0filed May 18, 2026
Mark W. HahnInsiderdirector
0.00%0filed May 18, 2026
Patricia C. HiranoInsiderofficer: SEE REMARKS
0.00%0filed May 18, 2026
Michael F. HuangInsiderofficer: Sr. VP of Clinical Development
0.00%0filed May 18, 2026
James GlasheenInsider
—0.10% of class, as filed—filed Apr 9, 2019
Manher JoshiInsiderofficer: Chief Development Officer
0.00%0filed May 18, 2026
Meredith ManningInsiderofficer: Chief Commercial Officer
0.00%0filed May 18, 2026
Nantahala Capital Management, LLCInstitution
—9.90% of class, as filed—filed Feb 12, 2021
Kevin NorrettInsiderofficer: Chief Business Officer
0.00%0filed May 18, 2026
Matthew PaulsInsiderdirector
0.00%0filed May 18, 2026
Peter KolchinskyInsider
—4.60% of class, as filed—filed Oct 5, 2023
Andrew SinclairInsiderdirector
0.00%0filed May 18, 2026
Vivo Opportunity, LLC2Strategic10 percent owner
0.00%0filed Mar 28, 2025
Birgitte VolckInsiderdirector
0.00%0filed May 18, 2026
  1. Vivo Ventures V, LLC's transaction reports restate only vehicles that traded; the 2017 ownership statement (15.51M) plus the 830.5K net shares acquired since is used instead.
  2. Vivo Opportunity, LLC reports a block also reported by Wellington Management Group LLP; it is counted once, under Wellington Management Group LLP.

13F

No 13F holders on record.

13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Ein #10.10%4.16MOct 3, 2024
Wellington Management Group LLP8.60%4.43M13GMay 15, 2026
BlackRock, Inc.6.90%3.54M13GApr 24, 2026
Avoro Capital Advisors LLCincl. Behzad Aghazadeh5.60%2.18M13GNov 14, 2024
State Street Corporation5.20%2.68M13GMay 12, 2026

Form 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Mar 27, 2026
Michael F. Huangofficer: Sr. VP of Clinical Development
Sale · 3 lots6,582$30.4439,823
Mar 27, 2026
Meredith Manningofficer: Chief Commercial Officer
Sale · 3 lots7,522$30.4464,507

House and Senate disclosures

Not reported.